KRAS and colorectal carcinoma: Beyond lung cancer, adagrasib plus cetuximab received accelerated approval in June 2024 for locally advanced or metastatic KRAS G12C-mutated CRC following prior chemotherapy, based on the phase I/II KRYSTAL-1 trial (NCT03785249).